Ronald W. Penczek Sells 443 Shares of Elevance Health, Inc. (NYSE:ELV) Stock

Elevance Health, Inc. (NYSE:ELV - Get Free Report) CAO Ronald W. Penczek sold 443 shares of Elevance Health stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $415.13, for a total value of $183,902.59. Following the completion of the transaction, the chief accounting officer now directly owns 1,847 shares of the company's stock, valued at approximately $766,745.11. This represents a 19.34 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Elevance Health Price Performance

Shares of Elevance Health stock traded up $13.89 during trading hours on Tuesday, hitting $423.44. The company's stock had a trading volume of 3,138,310 shares, compared to its average volume of 1,632,365. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.50 and a current ratio of 1.45. Elevance Health, Inc. has a 12-month low of $362.21 and a 12-month high of $567.26. The business has a 50 day moving average price of $391.45 and a two-hundred day moving average price of $432.42. The company has a market cap of $96.27 billion, a PE ratio of 16.53, a PEG ratio of 1.18 and a beta of 0.86.

Elevance Health (NYSE:ELV - Get Free Report) last posted its quarterly earnings results on Thursday, January 23rd. The company reported $3.84 earnings per share for the quarter, topping the consensus estimate of $3.80 by $0.04. Elevance Health had a return on equity of 18.28% and a net margin of 3.38%. Analysts expect that Elevance Health, Inc. will post 33.96 earnings per share for the current fiscal year.

Elevance Health Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 25th. Shareholders of record on Monday, March 10th will be issued a $1.71 dividend. This is an increase from Elevance Health's previous quarterly dividend of $1.63. This represents a $6.84 dividend on an annualized basis and a yield of 1.62%. The ex-dividend date is Monday, March 10th. Elevance Health's payout ratio is currently 26.71%.

Wall Street Analyst Weigh In

Several brokerages have issued reports on ELV. Truist Financial decreased their target price on shares of Elevance Health from $520.00 to $480.00 and set a "buy" rating for the company in a report on Monday, January 6th. Argus reiterated a "hold" rating and set a $405.40 target price on shares of Elevance Health in a research note on Wednesday, January 29th. Barclays lifted their target price on Elevance Health from $501.00 to $512.00 and gave the stock an "overweight" rating in a report on Friday, January 24th. StockNews.com raised Elevance Health from a "hold" rating to a "buy" rating in a report on Saturday, March 1st. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $485.00 price objective on shares of Elevance Health in a report on Friday, January 24th. Three analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $517.03.

Remove Ads

Institutional Trading of Elevance Health

Several hedge funds have recently bought and sold shares of the stock. Accredited Wealth Management LLC purchased a new position in shares of Elevance Health during the fourth quarter valued at about $25,000. Raelipskie Partnership bought a new position in Elevance Health during the third quarter valued at approximately $26,000. Flagship Wealth Advisors LLC purchased a new position in Elevance Health during the 4th quarter valued at approximately $26,000. OFI Invest Asset Management bought a new stake in Elevance Health in the 4th quarter worth approximately $29,000. Finally, WealthTrak Capital Management LLC purchased a new stake in shares of Elevance Health during the 4th quarter worth approximately $29,000. Hedge funds and other institutional investors own 89.24% of the company's stock.

About Elevance Health

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.